Clinical Report: Impact of Antimicrobial Timing in Suspected Infective Endocarditis

Overview

In clinically stable patients with suspected infective endocarditis (IE), deferring antimicrobial therapy until preliminary blood culture results are available does not increase 30-day mortality or adverse composite outcomes. Immediate empiric treatment showed no significant clinical benefit over delayed therapy in this population.

Background

Infective endocarditis is a serious infection with high morbidity and mortality, traditionally managed by prompt initiation of empirical antimicrobial treatment after blood cultures are obtained. Current guidelines recommend immediate therapy regardless of clinical severity, based largely on data from other infections and retrospective studies. However, the benefit of early treatment in hemodynamically stable patients without sepsis remains unclear, and concerns exist about overtreatment and antimicrobial resistance due to misdiagnosis and broad-spectrum regimens.

Data Highlights

*Composite endpoint includes 30-day mortality, new embolic events, or new bone and joint infection.

Key Findings

• Among 1230 bacteremia episodes with suspected IE, 55% received immediate empiric antimicrobial therapy, and 45% had therapy deferred until preliminary blood culture results.
• Overall 30-day mortality was low (5%) and did not differ between immediate and deferred treatment groups (5% vs 5%, P = .894).
• In 597 confirmed IE cases, the composite outcome of mortality, embolic events, or new bone/joint infection occurred in 26% of episodes, with no significant difference between groups (28% immediate vs 24% deferred, P = .304).
• Patients with sepsis, ICU admission, neutropenia, or other clear infection foci were excluded, focusing analysis on clinically stable patients.
• Deferring antimicrobial therapy until blood culture identification did not worsen clinical outcomes in stable patients with suspected IE.

Clinical Implications

For hemodynamically stable patients with suspected infective endocarditis, clinicians may consider deferring empiric antimicrobial therapy until preliminary blood culture results are available without compromising patient outcomes. This approach may reduce unnecessary broad-spectrum antimicrobial use and help limit antimicrobial resistance. Prompt therapy remains critical in patients with sepsis or severe presentations.

Conclusion

In clinically stable patients suspected of infective endocarditis, delaying antimicrobial treatment until blood culture results are available is not associated with increased mortality or adverse outcomes. These findings support a more individualized approach to antimicrobial timing in this population.

References

1. Osthoff et al. 2024 -- Timing of Antimicrobial Therapy in Infective Endocarditis: Is a Delay Justified?